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ABSTRACT
Immunoglobulin G4-related diseases (IgG4-RD) are a group 
of chronic relapsing–remitting inflammatory conditions, 
characterised by tissue infiltration with lymphocytes 
and IgG4-secreting plasma cells, fibrosis and a usually 
favourable response to steroids.
In this narrative review, we summarise the results of a 
systematic literature research, which was performed as 
part of the European Reference Network ReCONNET, aimed 
at evaluating existing clinical practice guidelines (CPGs) 
and recommendations in IgG4-RD. From 167 publications 
initially obtained from a systematic literature search, 
only one was identified as a systematic multispecialist, 
evidence-based, consensus guidance statement on 
diagnosis and treatment of IgG4-RD, which may be 
recommended for use as CPG in IgG4-RD.
With the recognition of a limited evidence based 
in this increasingly recognised disease, the group 
discussion has identified the following unmet needs: 
lack of shared classification criteria, absence of formal 
guidelines on diagnosis, no evidence-based therapeutic 
recommendations and lack of activity and damage indices. 
Areas of unmet needs include the difficulties in diagnosis, 
management and monitoring and the scarcity of expert 
centres.
INTRODUCTION
Immunoglobulin G4-related disease (IgG4-
RD) is an increasingly recognised immune- 
mediated chronic relapsing– remitting 
inflammatory condition, characterised by 
tissue infiltration with lymphocytes and 
IgG4-secreting plasma cells, fibrosis and a 
usually favourable response to steroids. The 
commonly shared features include tumour-
like swelling of involved organs, which in the 
majority of patients is indolent, particularly in 
early stages of disease. Pain is usually a conse-
quence of the obstruction or compression 
due to the presence of mass lesions and their 
complications. Multiorgan involvement may 
either be present at the same time (synchro-
nously) or different sites can be affected 
at various time periods (metachronously). 
Major presentations of IgG4-RD include type 
1 autoimmune pancreatitis, salivary gland 
disease, orbital disease and retroperito-
neal fibrosis. Irrespective of which organ or 
tissue is involved, the hallmarks of IgG4-RD 
are lymphoplasmacytic infiltrates rich in 
IgG4-positive plasma cells, storiform fibrosis 
and obliterative phlebitis. The clinical suspi-
cion may arise from elevated plasma IgG4 
levels, but the definitive diagnosis is based 
on histology and other cell-based diagnostics 
as serum concentration may be within the 
normal range. To prevent fibrosis progression 
and organ destruction, a treatment of induc-
tion and maintenance of remission is neces-
sary. The recommended first-line agents are 
Key messages
What is already known about this subject?
 ► Immunoglobulin G4-related disease (IgG4-RD) is a 
relatively new defined clinical entity with lack of ev-
idence base to guide clinical care.
 ► There is an unmet need for clinical practice guide-
lines for diagnosis, classification and standard of 
care in patients with IgG4-RD.
What does this study add?
 ► This systematic review reports the state of the art on 
existing clinical guidelines and unmet needs in the 
management of patients with IgG4-RD.
How might this impact on clinical practice?
 ► The European Reference Network on Rare and 
Complex Connective Tissue and Musculoskeletal 
Diseases (ReCONNET) will provide better and safer 
healthcare in IgG4-RD by promoting validated stan-
dard clinical guidelines.
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glucocorticoids. However, relapses are frequent during 
tapering, so  glucocorticoid-sparing immunosuppres-
sive agents are usually considered, although adequate 
controlled studies on their efficacy are lacking. Finally, 
surgery or radiotherapy may be necessary in case of 
serious organ damage.
In this narrative review, we summarise the results of a 
systematic literature research, which was performed as 
part of the ERN ReCONNET project, dedicated to eval-
uation of currently available clinical practice guidelines 
(CPGs) or recommendations. Subsequently, clinicians’ 
and patients’ unmet needs of IgG4RD were discussed.
METHODS
ReCONNET network
ERN ReCONNET (Rare CONnective tissue and muscu-
loskeletal diseases NETwork) is a European Reference 
Network on Rare and Complex Connective Tissue and 
Musculoskeletal Diseases funded by the European 
Union’s Health Program to promote better and safer 
healthcare, define proper organisational assessment 
and identify standard and cost-effective pathways for 
the management of rare and complex connective tissue 
diseases. The Network includes rheumatologists, intern-
ists and immunologists from 26 selected centres in eight 
different countries across Europe (http:// reconnet. 
ern- net. eu). One of the first network targets was eval-
uate currently available CPGs or recommendations in a 
systematic literature search to identify potential unmet 
needs in the most relevant rare autoimmune diseases.
Systematic literature search
We carried out a systematic search in PubMed and 
EMBASE based on controlled terms (MeSH and Emtree) 
and keywords of the disease and publication type (CPGs). 
We reviewed all published articles in order to identify 
existing CPGs on diagnosis, monitoring and treatment, 
according to the Institute of Medicine 2011 definition 
(CPGs are statements that include recommendations 
intended to optimise patient care that are informed by 
a systematic review of evidence and an assessment of the 
benefits and harms of alternative care options).
The disease coordinators (DCs) of the ERN 
ReCONNET for IgG4-RD had assigned the work on CPGs 
to the healthcare providers (HCPs) involved. Moreover, 
in order to implement the list of guidelines provided by 
PubMed and EMBASE search, the group performed also 
a hand search. A first screening among papers included 
in the final list (systematic search+hand search) based 
on title and abstract selected evidence-based medicine 
guidelines. A general assessment of the CPGs had been 
performed following the AGREE II tool checklist not for 
formal appraisal but only to inform discussion. A discus-
sion group composed of DCs (LI and TA) and disease 
representative (DR) was set for the evaluation of the 
existing CPGs and to identify the unmet needs.
More precisely, the following search strategy was used 
to identify publications from the databases:
Medline (PubMed)
(IgG4-related [All Fields] AND (“disease”[MeSH Terms] 
OR “disease”[All Fields])) AND (“Practice Guide-
line”[Publication Type] OR “Practice Guidelines As 
Topic”[MeSH Terms] OR Practice Guideline[Publica-
tion Type] OR “Practice Guideline”[Text Word] OR 
“Practice Guidelines”[Text Word] OR “Guideline”[Pub-
lication Type] OR “Guidelines As Topic”[MeSH Terms] 
OR Guideline[Publication Type] OR “Guideline”[Text 
Word] OR “Guidelines”[Text Word] OR “Consensus 
Development Conference”[Publication Type] OR 
“Consensus Development Conferences As Topic”[MeSH 
Terms] OR “Consensus”[MeSH Terms] OR “Consen-
sus”[Text Word] OR “Recommendation”[Text Word] OR 
“Recommendations”[Text Word] OR “Best Practice”[-
Text Word] OR “Best Practices”[Text Word]).
EMBASE
(‘immunoglobulin g4 related disease’/exp OR ‘igg4 
related disease’ OR ‘immunoglobulin g4 related disease’) 
AND (‘practice guideline’/exp OR ‘practice guideline’ 
OR ‘practice guidelines’/exp OR ‘practice guidelines’ 
OR ‘clinical practice guideline’/exp OR ‘clinical practice 
guideline’ OR ‘clinical practice guidelines’/exp OR ‘clin-
ical practice guidelines’ OR ‘clinical practice guidelines 
as topic’/exp OR ‘clinical practice guidelines as topic’ 
OR ‘guideline’/exp OR ‘guideline’ OR ‘guidelines’/exp 
OR ‘guidelines’ OR 'guidelines as topic’/exp OR ‘guide-
lines as topic’ OR ‘consensus development’/exp OR 
‘consensus development’ OR ‘consensus development 
conference’/exp OR ‘consensus development confer-
ence’ OR ‘consensus development conferences’/exp OR 
‘consensus development conferences’ OR ‘consensus 
development conferences as topic’/exp OR ‘consensus 
development conferences as topic’ OR ‘consensus’/exp 
OR ‘consensus’ OR ‘recommendation’ OR ‘recommen-
dations’) AND [embase]/lim NOT [medline]/lim.
STATE OF THE ART ON CPGS
Identification of existing CPGs
The systematic literature search initially identified a total 
of 165 citations by the ERN ReCONNET central team 
(figure 1). After performing title and abstract evaluation 
by disease representatives, eight papers were selected for 
further review. After full-text review by the disease coor-
dinators, four CPGs were finally selected for further eval-
uation using full-text assessment,1–4 which were subse-
quently endorsed by the disease representatives.
CPG characteristics
The general characteristics of the four CPGs are summa-
rised in table 1. Of the four preselected publications, only 
one was identified as a systematic multispecialist, evidence-
based, consensus guidance statement on diagnosis and 
treatment of IgG4-RD, which may be recommended 
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for use as CPG.1 This publication was an International 
Consensus Guidance Statement on the management and 
treatment of IgG4-RD, resulting from an expert panel of 
42 IgG4-RD experts from eight medical specialties (18 
gastroenterologists, 13 rheumatologists and 11 other 
specialists and subspecialists). Although these guide-
lines are relevant for clinical practice, the evidence level 
reported in the paper varies between IIb and IV, given 
the lack of solid and endorsed classification criteria and 
randomised controlled trials (RCTs) in this field.1 As a 
result, there was broad consensus that
 ► The most accurate assessment of IgG4-RD is based on 
a full clinical history, physical examination, selected 
laboratory investigations and appropriate radiology 
studies.
 ► Diagnostic confirmation by biopsy is strongly recom-
mended for the exclusion of malignancies and other 
IgG4-RD mimics.
 ► All patients with symptomatic, active IgG4-RD and a 
subset of patients with asymptomatic disease require 
treatment, some urgently.
 ► Glucocorticoids are the first-line agent for remission 
induction unless contraindications are present.
 ► Some but not all patients require the combination 
of glucocorticoids and a steroid-sparing immunosup-
pressive agent from the start of treatment.
 ► Following a successful course of induction therapy, 
certain patients benefit from maintenance therapy.
 ► Re-treatment with glucocorticoids is indicated in 
patients who relapse off of treatment following 
successful remission induction. Following relapse, the 
introduction of a steroid-sparing agent for continua-
tion in the remission maintenance period should be 
considered.
The remaining three selected GPGs were only reviews 
or consensus statements on existing data for terminology, 
pathology and immunopathology of IgG4-RD.2–4 They 
lack accepted methods for systematic review and repre-
sent rather expert consensus than real guidelines or 
recommendation with suboptimal clinical practice use, 
which may not be recommended as a guideline for use 
(table 1).
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Figure 1 Stepwise search strategy for selection and evaluation of published clinical practice guidelines for IgG4-RD.
Table 1 Summary of the evaluation of existing guidelines
Author and year Description Reference
Khosroshahi et al, 2015 Systematic review, multiple specialists, guidelines for diagnostic and treatment, 
so far first real guidelines; very helpful for the physician in clinical practice
1
Deshpande et al, 2013 Review on existing data for terminology, pathology and immunopathology, no 
real guidelines, no systematic review; recommendations are lacking, so the 
usefulness of this paper is limited
2
Deshpande et al, 2012 Consensus statement on pathology, only expert opinion, no clear systematic 
review; no systematic methods for formulating recommendations key 
histopathological features and IgG4 assessment are clearly defined
3
Stone et al, 2012 Review on terminology based on expert opinion. Although experts from 
different specialties were present, this is rather expert consensus than a clear 
recommendation; no systematic guidelines are reported and key messages are 
not easily identifiable
4
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UNMET NEEDS
Clinicians’ unmet needs
The following unmet needs have been identified and 
discussed by the DCs and DRs:
Lack of shared classification criteria
There is no international consensus on classification 
criteria for IgG4-RD. Therefore, development of vali-
dated classification criteria should be the first step to 
guide clinicians in stratifying patients and to provide the 
basis for further collaborative and comparative research 
studies in the field. In this sense, the European League 
Against Rheumatism (EULAR) and American College of 
Rheumatology (ACR) are currently jointly supporting a 
Task Force for the development of classification criteria 
for IgG4-RD that will hopefully be available in the near 
future.
No formal guidelines for diagnosis available
Diagnosis of IgG4-RD is challenging, given the hetero-
geneity of clinical symptoms and laboratory results. The 
prevalence of IgG4-RD is probably underestimated, espe-
cially in Europe and North America, where the aware-
ness of its existence may be lower than in Asian countries, 
where the disease was initially described. Although serum 
IgG4 concentrations may be helpful, they have certainly 
lost importance in the diagnosis.5 Histology is still the 
gold standard for diagnosis, but evidence-based criteria 
in this field are scarce. In the last years, several studies 
have been published on possible diagnostic markers and 
predictive factors. For example, assessment of plasmablast 
levels by flow cytometry has recently emerged as a prom-
ising new diagnostic modality.6 However, more evidence 
in this field is necessary to provide the basis for standard-
ised algorithms in the diagnostic process. Further studies 
are required that need to be performed in an interna-
tional collaborative setting, including all involved disease 
specialists, that is, rheumatology, gastroenterology, 
vascular medicine, surgery, radiology, pathology and clin-
ical immunology.
Indices for disease activity and damage are lacking
Similar to other inflammatory rheumatic diseases, 
IgG4-RD presents with relapsing–remitting courses that 
may eventually result in tissue damage. Therefore, stand-
ardised indices for disease activity and damage need to be 
developed and validated. In addition, the place and rele-
vance of imaging techniques (eg, ultrasound, CT, MRI 
and PET scans) in diagnosis and follow-up of the disease 
should be evaluated.
Therapy is not evidence based
Although IgG4-RD frequently represents an indo-
lent condition, treatment is usually required to reduce 
chronic inflammation and to prevent progressive tissue 
fibrosis. Furthermore, untreated IgG4-RD with elevated 
inflammatory markers may lead to secondary AA amyloi-
dosis.7 8 Therefore, symptoms and risk of irreversible 
organ damage due to fibrosis and also modulation of the 
underlying chronic inflammatory condition should be 
taken into account for treatment decisions. Single-centre 
observations suggest favourable responses to gluco-
corticoids, which are regarded as first-line therapy, but 
relapses are frequently observed during steroid tapering. 
Disease-modifying drugs (DMARDs) have proven efficacy 
in some cases, but large RCTs investigating the outcome 
of various DMARDs are lacking. A recent nationwide 
retrospective study showed that rituximab is effective for 
both induction therapy and relapse treatment in IgG4-
RD.9 Hence, RCTs are urgently required in the field, but 
difficult to conduct given the rarity and heterogeneity of 
the disease. Alternatively, evidence from non-randomised 
or uncontrolled studies may also be used for further 
developments. In addition, validated tools for treatment 
response are lacking and no treat-to-target criteria are 
available. Recently, an IgG4-RD responder index10 has 
been developed and an international validation study is 
ongoing. To date, this index is the only available instru-
ment to assess IgG4-RD and its use needs to be encour-
aged in clinical practice.
Patient unmet needs
IgG4-RD represents a relatively new disease entity and 
awareness of the disease among healthcare providers is 
still inadequate and limited to few disease experts. Subse-
quently, the lag time from symptom onset to diagnosis is 
still unacceptably high and may be associated with accrual 
of irreversible organ damage before specific treatments 
are provided.
Each patient is different in relation to their symptoms 
as well as the approach of their care. Most care is also 
not evidence based, which may be an additional burden 
for the patient as some healthcare systems only support 
evidence-based care. Therefore, patients with IgG4-RD 
require special attention, especially with respect to inter-
disciplinary dialogue with treating physicians, individual 
support from patient representatives as well as guidance 
to address the psychosocial impact of the disease.
Centres of expertise for IgG4-RD are currently limited 
and not easy to identify by patients. In addition, the 
patient support system is still insufficient, as there are 
almost no disease-specific patient organisations estab-
lished at the moment on national and international level.
In conclusion, much effort is needed at multiple levels 
to meet the specific demands of patients suffering from 
IgG4-RD in providing optimised patient care, which may 
hopefully be accomplished in the framework of the ERN 
ReCONNET.
CONCLUSIONS
IgG4-RD is a relatively new defined clinical entity. There-
fore, formal disease classification and guidelines for 
diagnosis and treatment are still widely lacking. Given 
the rarity and heterogeneity of this disease, RCT may 
only be accomplished in international multicentre trials 
with support of pharmaceutical companies. The current 
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development of disease classification criteria by the 
EULAR and ACR task force will be the first step to harmo-
nise terminology and to provide the basis for further 
collaborative studies on diagnostic recommendations 
and treatment guidelines, which need to be endorsed by 
scientific international societies (ie, EULAR, ACR). In the 
absence of RCTs, the implementation of non- randomised 
pilot studies will help to increase the level of evidence of 
therapeutic guidelines.
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